search icon
      blog search icon

      What Drove The Paratek Pharmaceuticals (PRTK) Stock Up 9% During Afterhour Trading? - Stocks Telegraph

      By Fahim Awan

      Published on

      August 5, 2021

      8:11 AM UTC

      What Drove The Paratek Pharmaceuticals (PRTK) Stock Up 9% During Afterhour Trading? - Stocks Telegraph

      After-hours trading on Wednesday saw a rise of 8.84% for Paratek Pharmaceuticals Inc. (PRTK) at $5.91. At the end of the regular trading session, PRTK stock gained 1.58% to $5.43. PRTK stock traded between $5.32 and $5.49 on the day. Over the past 100 days, PRTK stock has traded 0.74 million shares, which is higher than its trading volume of 0.52 million shares in the session. In the last five days, PRTK stock has declined by -1.63%, while in the last month, it has dropped by -19.67%. PRTK stock spikes after its drug is cited in an updated CDC report.

      Which PRTK drug has been included?

      The goal of Paratek is to develop and commercialize novel therapeutics for the treatment of life-threatening diseases and other health threats, for civilian, national and military audiences. Nuzyra (omadacycline), PRTK’s lead commercial product, is an intravenous and oral antibiotic used to treat adults suffering from community-acquired pneumonia and acute skin and skin structure infections. Zai Lab and PRTK have a collaboration agreement about omadacycline development and commercialization in Greater China and PRTK retains all rights to the drug globally.

      The Center for Disease Control and Prevention (CDC) has included Paratek’s lead drug NUZYRA in their updated report, announced the company in a press release yesterday. The report by the CDC was entitled “Antimicrobial Treatment and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism Response”.

      • PRTK’s new alternative agent, NUZYRA, has been added to the list of agents that can be used to treat, prevent, and treat those with primary bubonic and pharyngeal plague infections.
      • It is recognized that Y. pestis, the bacterium responsible for plague in the United States and elsewhere, could be a weapon of bioterrorism.
      • Clinical staff and public health agencies must make rapid and informed decisions if they are to mitigate a bioweapon attack with Y. pestis.
      • As a medical countermeasure for civilian and military personnel during these types of public health emergencies, NUZYRA is included as part of the updated recommendation from the CDC.
      • This further validates the practical clinical utility of this modernized tetracycline antibiotic by PRTK for such emergency situations.
      • It is critical to ensure national security to develop new antibiotics that can combat potential biosecurity threats, especially as antimicrobial resistance increases.

      How PRTK Stock went through it?

      In order to assist in the development of comprehensive recommendations, the CDC conducted systematic literature reviews on the treatment of plague in humans and other relevant topics and has recommended PRTK’s drug as an alternative. Paratek (PRTK) conducted a research study of NUZYRA against pathogenic agents, including Y. pestis, in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

      More From Stocks telegraph